'Immediate' Steps To Lower Drug Prices: The HHS Action Plan
Executive Summary
Many of US drug pricing blueprint's proposals could be accomplished administratively, but will still be shaped by stakeholder feedback.
You may also be interested in...
US Drug Pricing: What A Difference A Year Makes
Drug makers were optimistic going into 2018 about the political climate and drug pricing environment, but the outlook is more tenuous heading into 2019. Now is the time when industry raises prices on mature, marketed drugs and it's unclear how those hikes may be tempered or what the backlash might be.
Why The M&A Boom Many Expected In 2018 Didn’t Happen
High valuations, an uncertain biopharma macro environment and widespread use of US tax reform benefits for share buybacks and capital investments resulted in less major M&A than expected. Opinions vary widely on whether 2019 will be any different.
Why The M&A Boom Many Expected In 2018 Didn’t Happen
High valuations, an uncertain biopharma macro environment and widespread use of US tax reform benefits for share buybacks and capital investments resulted in less major M&A than expected. Opinions vary widely on whether 2019 will be any different.